(NGSX) Mcap 25 M/Cash 45 M/FDA Panel 9th FEB !!!!

[Biotechmaster]

This LOW FLOAT MONSTER trading BELOW CASH and awaiting FDA approval within 45 days . Qutenza is already approved for another indication thats why it has a very high chance for FDA approval .
This low float sleeping giant is almost unknown to the most investors means the stock will explode once the investor discover this low float monster .

Anesthetic and Analgesic Drug Products Advisory Committee Meeting Scheduled for February 9, 2012

NeurogesX announced the FDA acceptance of the sNDA filing on November 14, 2011, and noted the Agency's goal is to review and act on the sNDA by March 7, 2012 under the Prescription Drug User Fee Act IIII (PDUFA).


We could see $3++ after FDA panel ...GLTA


Neurogesx (NGSX)

Market Cap: $ 25.3 M
Cash : $ 45.2 M
Price : 0.88 $


Shares Out : 29.6 M ( 19 M shares held by Insider + Institutions)
LOW FLOAT : Only 10 M shares


Great Pipeline



HEAVY Buying by Institutions



Institutions and Insiders holding together around 19 Mil shares thats the highest level in the history of this conpany .





NeurogesX Confirms FDA Advisory Committee to Review sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)

Anesthetic and Analgesic Drug Products Advisory Committee Meeting Scheduled for February 9, 2012

NeurogesX announced the FDA acceptance of the sNDA filing on November 14, 2011, and noted the Agency's goal is to review and act on the sNDA by March 7, 2012 under the Prescription Drug User Fee Act IIII (PDUFA).